La cadena de opciones muestra datos clave de las opciones de acciones de Cineverse a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cineverse..

Cineverse (NASDAQ:CNVS) Bolsa, Cadena de Opciones

Cineverse

Cineverse Corp is a main streaming technology and entertainment company. It operates portfolios of owned and operated streaming channels, all powered by its, proprietary technology platform. Cineverse features enthusiast brands for subscription video on demand (SVOD), advertising-based video on demand (AVOD), and free, ad-supported streaming television (FAST) channels. The company earns fees for the distribution of content in the home entertainment markets via several distribution channels, including digital, video-on-demand, and physical goods (e.g., DVDs and Blu-ray Discs) (Base Distribution).

Cineverse Corp

<ul>
<li>HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic&nbsp;mastocytosis.</li>
<li>Treatment shows potent&nbsp;downregulation of oncogenic KIT mutations with no observed systemic toxicity.</li>
<li>IND filing expected early 2026, opening pathway to first-in-human trials.</li>
</ul>
Preclinical Milestones:
<ul>
<li>Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations.</li>
<li>Significant inhibition of tumor growth in GIST and mast cell tumor animal models following systemic administration of HT-KIT.</li>
<li>No observable off-target toxicity in liver, kidney, or bone marrow, suggesting a favorable safety profile.</li>
</ul>

Biotech

News

General

HOTH

Hoth Therapeutics Announces Preclinical Data For HT-KIT, With IND Filing Expected In Early 2026; Says 'HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis.'

ABEO

Abeona Therapeutics To Sell Priority Review Voucher For $155M Following FDA Approval Of ZEVASKYN

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.38) by 25.36 percent. This is a 66.12 percent increase over losses of $(3.04) per share from the same period last year. The company reported quarterly sales of $24.07 million which missed the analyst consensus estimate of $26.26 million by 8.34 percent. This is a 14.07 percent decrease over sales of $28.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

AGEN

Agenus Q1 EPS $(1.03) Beats $(1.38) Estimate, Sales $24.07M Miss $26.26M Estimate

SGRY

Surgery Partners Q1 2025 Adj. EPS $0.04 Misses $0.05 Estimate, Sales $776.00M Miss $777.07M Estimate

SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 50 percent. This is a 40 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $408.16 million which beat the analyst consensus estimate of $406.50 million by 0.41 percent. This is a 8.44 percent increase over sales of $376.40 million the same period last year.

SLQT

SelectQuote Q3 EPS $0.03 Beats $0.02 Estimate, Sales $408.16M Beat $406.50M Estimate

Rosenblatt analyst Chris Brendler maintains TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy and lowers the price target from $4.5 to $4.

Price Target

Analyst Ratings

WULF

Rosenblatt Maintains Buy on TeraWulf, Lowers Price Target to $4

DeFi Development Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) announced on Monday that it had purchased 172,670 Solana (CRYPTO: SOL/USD) at an average purchase price of $136.81, valued at <a target="_blank" href="https://www.benzinga.com/topic/solana" rel="noreferrer noopener">approximately $23.6 million</a>.
This marks the company's 10th Solana purchase under its digital asset treasury strategy and its largest purchase.
DeFi Development Corp now holds 595,988 SOL, valued at approximately $102.7 million, including staking rewards.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/05/45217853/exclusive-defi-development-corp-expands-digital-asset-portfolio-holds-58-5-million-in-solana-tokens" rel="noreferrer noopener">DeFi Development Corp Expands Digital Asset Portfolio, Holds $58.5 Million In Solana Tokens</a>
As of May 12, DeFi Development had 2.04 million total outstanding shares. The SOL per Share (SPS) was 0.293, or $50.42.
As with all previously purchased tokens, the most recently purchased SOL will be held long-term and staked to various validators, including DeFi Dev Corp's own Solana validators, to generate native yield.
Price Action: DFDV stock traded higher by 12% to $84 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/45081468/sofi-stock-pops-as-revenue-soars-and-ceo-teases-crypto-comeback" target="_blank" rel="noreferrer noopener">SoFi Stock Pops As Revenue Soars And CEO Teases Crypto Comeback</a></li>
</ul>
Photo: Lee Wa Da via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Market-Moving Exclusives

Exclusives

DFDV

EXCLUSIVE: DeFi Development Makes Record Solana Purchase, Surpasses $100 Million In Treasury Holdings

Buybacks

V2X Board Approves Share Repurchase Program Up To $100M

Markets

$SOL

EXCLUSIVE: DeFi Development Tells Benzinga Co. Purchases Record 172,670 SOL, Says Co Now Holds 595,988 SOL Valued At Approximately $102.7M

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and raises the price target from $12 to $15.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Raises Price Target to $15

Needham analyst Laura Martin reiterates Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Buy and maintains $88.5 price target.

Reiteration

ROKU

Needham Reiterates Buy on Roku, Maintains $88.5 Price Target

Perpetua Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPTA#NASDAQ">PPTA</a>) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.02) by 500 percent. This is a 140 percent decrease over losses of $(0.05) per share from the same period last year.

PPTA

Perpetua Resources Q1 EPS $(0.12) Misses $(0.02) Estimate

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) with a Buy and maintains $7 price target.

OCGN

Chardan Capital Maintains Buy on Ocugen, Maintains $7 Price Target

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) affirms FY2025 Adj EPS guidance from $6.75-$7.75 to $6.75-$7.75 vs $7.41 analyst estimate..

Guidance

NRG Energy Affirms FY2025 Adj EPS Guidance of $6.75-$7.75 vs $7.41 Est

NRG Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) reported quarterly earnings of $2.68 per share which beat the analyst consensus estimate of $1.49 by 79.87 percent. This is a 16.02 percent increase over earnings of $2.31 per share from the same period last year. The company reported quarterly sales of $8.59 billion which beat the analyst consensus estimate of $7.83 billion by 9.69 percent. This is a 15.56 percent increase over sales of $7.43 billion the same period last year.

NRG Energy Q1 Adj. EPS $2.68 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

Needham analyst Laura Martin maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $14 to $18.

MGNI

Needham Maintains Buy on Magnite, Raises Price Target to $18

Seagate Data Storage Technology Pte. Ltd. (the "Company"), a subsidiary of Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) ("Seagate"), today announced that the Company intends to offer, subject to market and other conditions, $400.0 million in aggregate principal amount of senior notes due 2030 (the "Notes") in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and in offshore transactions under Regulation S under the Securities Act. The Notes are expected to be guaranteed by Seagate, Seagate Technology Unlimited Company and Seagate HDD Cayman.
In connection with this offering, Seagate HDD Cayman issued a notice of conditional full redemption providing for the redemption (the "Redemption") of all of its outstanding 4.875% Senior Notes due 2027 (the "2027 Notes"), at a redemption price equal to 100% of the principal amount of the 2027 Notes, plus a "make-whole" premium set forth in the indenture governing the 2027 Notes, plus accrued and unpaid interest to, but excluding, the redemption date (the "Redemption Price"). The Redemption is conditioned upon receipt by the Company on or prior to the redemption date of net proceeds from one or more financing transactions in an amount, together with cash on hand, sufficient to pay the Redemption Price on or prior to the redemption date.
The Company intends to use the net proceeds from the offering of the Notes, together with cash on hand, to finance the Redemption and to pay related fees and expenses.

Seagate Subsidiary Intends To Offer $400M Senior Notes Due 2030

Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) today announced expanded coverage of the Garmin Navigation Database to include the South Pacific region, including Australia, New Zealand and surrounding countries. Previously available to aircraft owners and operators in the Americas and Europe, the Garmin Navigation Database delivers a new option for South Pacific region customers to incorporate the latest aviation navigation information into their Garmin avionics. Offered for a variety of Garmin aviation products, including integrated flight decks, navigators, flight displays, portables and more, the new Garmin Navigation Database for the South Pacific region introduces a variety of cost-effective ways to purchase database updates. This includes single updates, annual bundle options and OnePak&#x2122; subscriptions for all compatible avionics in an aircraft.
 &nbsp;

GRMN

Garmin Expands Aviation Navigation Coverage to Include South Pacific, Offering Cost-Effective Updates

Chardan Capital analyst Daniil Gataulin maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $38 price target.

QURE

Chardan Capital Maintains Buy on uniQure, Maintains $38 Price Target

The Founder, CEO, and CIO of Ark Invest, Cathie Wood, has highlighted the rising applications of artificial intelligence and how it is poised to impact not only autonomous taxi networks and humanoid robots but also the health care space.
What Happened: According to ARK's proprietary Multiomics Flywheel, Wood highlighted in her recent X post that autonomous taxi networks and humanoid robots are likely to be the largest AI applications during the next five and ten years, respectively; however, &#8220;health care is likely to be the most profound.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While autonomous taxi networks and humanoid robots are likely to be the largest <a href="https://twitter.com/hashtag/AI?src=hash&amp;ref_src=twsrc%5Etfw">#AI</a> applications during the next five and ten years, respectively, health care is likely to be the most profound. Thank you <a href="https://twitter.com/NMDespotARK?ref_src=twsrc%5Etfw">@NMDespotARK</a> for thought leadership in the multiomics space! <a href="https://t.co/C33JfypivU">https://t.co/C33JfypivU</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1921291392271167893?ref_src=twsrc%5Etfw">May 10, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The post shared by Ark&#8217;s multiomics analyst, Nemo M Despot, underscored that &#8220;AI is powering a self-reinforcing loop that accelerates every aspect of multiomics—from generating biological data, to diagnosing diseases, to developing new drugs and cures.&#8221;
Multiomics is a biological analysis approach that integrates data from multiple &#8220;omic&#8221; fields, like genomics, transcriptomics, proteomics, and metabolomics, to gain an understanding of biological systems.
This integrated approach helps researchers uncover complex relationships, identify biomarkers, and ultimately understand the mechanisms behind disease and other biological processes.
He also highlights that companies like Twist Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 10X Genomics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), and Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) are developing increasingly powerful tools to sequence and analyze DNA faster and more cost-effectively.
Despot stated that AI-powered molecular diagnostics are transforming early disease detection and enabling precise stratification of individual patient biological profiles.
&#8220;AI leverages data from multiomic tools and diagnostics to design more effective drugs, delivering results with higher success rates more quickly and less expensively,&#8221; he said.
According to him, these next-generation therapies are:
<ul class="wp-block-list">
<li>Approximately 20 times more valuable than standard drugs.</li>
</ul>
<ul class="wp-block-list">
<li>Two to four times more effective than even today's best-in-class precision medicine.</li>
</ul>
<ul class="wp-block-list">
<li>The new cures can address even rare diseases economically.</li>
</ul>
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a>
Why It Matters: Trump, in a Truth Social post, said that he will <a href="https://www.benzinga.com/general/health-care/25/05/45339399/trump-says-prescription-drug-prices-set-to-drop-by-30-to-80-almost-immediately-thanks-to-most-favored-nation-plan-mark-cuban-urges-president-to-force-tran">sign an executive order</a> on Monday at 9:00 a.m. ET, which will lead the prescription drug and pharmaceutical prices to drop by 30% to 80%.
&#8220;They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World,&#8221; he added.
Trump also believes that healthcare costs in the U.S. will be reduced after this move, and it would save &#8220;trillions of dollars.&#8221;
This action by Trump is anticipated to most significantly <a href="https://www.benzinga.com/general/health-care/25/05/45341590/trumps-drug-pricing-executive-order-could-rattle-pharma-stocksprice-cuts-up-to-80">affect Medicare Part B drugs</a>, primarily outpatient prescriptions and biological products, as their prices are directly controlled by the Centers for Medicare &amp; Medicaid Services (CMS).
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Drug Name</th>
<th>Manufacturer(s)</th>
<th>Total Spending</th>
<th>Primary Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keytruda</td>
<td>Merck &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) 
<path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path>
<div jsname="ntFePb" class="GRl5yb a8pxAe" style="max-height: 120px; visibility: inherit;"></div>
<div></div>
</td>
<td>$4.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Eylea</td>
<td>Regeneron Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>$3.4B</td>
<td>Macular degeneration</td>
</tr>
<tr>
<td>Prolia/Xgeva</td>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>$2.1B</td>
<td>Osteoporosis, bone metastases</td>
</tr>
<tr>
<td>Opdivo</td>
<td>Bristol-Myers Squibb Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>$2.0B</td>
<td>Cancer (various types)</td>
</tr>
<tr>
<td>Darzalex</td>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>$1.9B</td>
<td>Multiple myeloma</td>
</tr>
<tr>
<td>Avastin</td>
<td>Roche Holdings AG&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTCQX">RHHBY</a>)</td>
<td>$1.8B</td>
<td>Cancer (various types)</td>
</tr>
</tbody>
</table>
</figure>
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Monday. The SPY was up 2.78% to $564.34, while the QQQ advanced 3.75% to $506.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Friday, the SPY was down 0.13% to $564.34, while the QQQ declined 0.066% to $487.97
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45341850/economists-warn-of-empty-shelves-if-goods-stop-coming-from-china-amid-falling-inventory-to-sales-ratio-and-potential-tariffs">Economists Warn Of &#8216;Empty Shelves&#8217; If Goods Stop Coming From China Amid Falling Inventory-To-Sales Ratio And Potential Tariffs </a></li>
</ul>
Photo Courtesy: PeopleImages- Yuri A On Shutterstock

Analyst Color

Equities

Government

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

ETFs

AMGN

ILMN

REGN

RHHBY

TWST

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots

Entertainment

Press Releases

Cineverse Chooses Iconic Events Releasing as Distribution Partner for the Theatrical Return of Comedy Horror Franchise The Toxic Avenger

Cineverse Hires Tim Russell, Promotes Terry City as Direct Advertising Sales Team Expands

Cineverse's RetroCrush Acquires Exclusive Streaming Rights to Classic Sci-Fi Anime Series "Future Boy Conan" from GKIDS

Cineverse Expands Existing Line of Credit Facility with East West Bank to $15 Million with a Three-Year Term

Cineverse Acquires U.S. Rights to Lynchian Thriller The Things You Kill; Fall Theatrical Release Planned

Cineverse Launches "Land of the Lost" and "So…Real" FAST Channels on Philo

Cineverse Announces Start of Production for Holiday Horror Film, Silent Night, Deadly Night

Cineverse Promotes John Squires and Megan Vavarro to Co-Managing Directors of Leading Horror Brand, Bloody Disgusting

/C O R R E C T I O N -- Cineverse Corp./

Cineverse Acquires U.S. Rights for Return to Silent Hill, The Newest Installment in the popular Video Game Horror Film Franchise from Davis Films

CNVS

Anghami

BloomZ

Brera Holdings PLC - Class B Ordinary Shares

Brera Holdings

Pop Culture Group Co., Ltd - Class A Ordinary Shares

Pop Culture Gr

CuriosityStream Inc. - Class A Common Stock

CuriosityStream

Dolphin Entertainment, Inc. - Common Stock

Dolphin Entertainment

Eventbrite

Gaia

Global Mofy AI Limited - Class A Ordinary Shares

Global Mofy AI

Kuke Music Holding Limited American Depositary Shares (each representing ten (10) Class A Ordinary Shares)

Comments

Cineverse

Cineverse (CNVS) Opciones

Cineverse (NASDAQ:CNVS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL